Free Trial

Sarepta Therapeutics Gets FDA Nod, Drops Warning (or Opportunity?)

Sarepta Therapeutics stock jumped more than 30% in May 2023 following FDA approval of its Duchenne muscular dystrophy treatment, Elevidys; image of girl with muscular dystrophy on beach

Key Points

  • Sarepta Therapeutics stock jumped more than 30% in May 2023 following FDA approval of its Duchenne muscular dystrophy treatment, Elevidys.
  • Five weeks later, the stock fell as much as 15% when Elevidys was formally announced.
  • Roughly four out of five analysts covering the stock still call it a buy and the average target of $178 implies 56% upside over the next 12 months.
  • 5 stocks we like better than Sarepta Therapeutics

On May 15, Sarepta Therapeutics Inc. NASDAQ: SRPT learned that its treatment for Duchenne muscular dystrophy (DMD) was recommended for approval by the Food and Drug Administration (FDA) advisors. Naturally, the stock jumped more than 30% to a two-year high.

Five weeks later, when Elevidys was formally announced as the first gene therapy for the inherited muscular disease, shares of the Cambridge-based company fell as much as 15%. 


The strange turn of events highlights the unpredictable nature of the biotechnology industry and its appropriateness solely for high-risk investors. It also presents a crossroads for a stock that has long been admired by Wall Street research groups.

In the aftermath of Elevidys getting a closely contested thumbs up from U.S. regulatory advisors, several analysts were quick to crown Sarepta the next big thing in biotech. Price targets were raised significantly.

But with the stock suddenly back at its lowest level since November 2022, shareholders and prospective investors are left asking, "Will the real Sarepta Therapeutics stock please stand up?"

Why is Sarepta Therapeutics Stock Down?

While the Elevidys approval is undoubtedly good news for families impacted by the severe childhood disease, the implications for Sarepta’s financial health is unclear. 

For starters, the FDA’s accelerated approval was limited to DMD patients who are between the ages of four and five years and who have the ability to walk. Sarepta’s FDA application, on the other hand, specified patients of all ages with the ability to walk. 

This puts the spotlight on results from a late-stage study of Elevidys, which aren’t expected until later this year. If that data is strong, it could push the FDA to expand the treatment’s use to other age groups. If it disappoints, then the current limited approval could stand. 

For now, the market is taking the glass-half-empty approach. While accelerated approval is a big positive, some say it is outweighed by its age limits and uncertainty around future label expansion.

Last week, Evercore ISI became the first firm to downgrade Sarepta shares to "hold," saying the path to expand the label is tough. The analyst also noted that obtaining Elevidys approval as a therapy for patients who are unable to walk may face significant roadblocks. Credit Suisse maintained its cautious stance, calling the stock a "hold" (and despite it, issuing a $141 price target). 

As part of the FDA’s accelerated approval pathway, Sarepta Therapeutics must complete a post-marketing confirmatory trial. Top-line results for the fully enrolled EMBARK Phase 3 trial are expected in the fourth quarter of 2023. 

Where Does Sarepta Therapeutics Go from Here?

Barring other major developments around the Elevidys approval or Sarepta’s other products and pipeline candidates, the stock could be range bound for the next several months. If sentiment shifts in one direction or the other, it's likely SRPT gaps lower — or refills Friday’s gap (if not the May 15 gap).

While pockets of negativity have weighed on Sarepta shares in recent days, the overarching Street opinion is bullish. Roughly four out of five analysts covering the stock call it a "buy." As is common with biotech names, price targets are in a wide range. The average target of $178 implies 56% upside over the next 12 months. 

Closely followed analysts at J.P. Morgan, Goldman Sachs and RBC Capital see Saretpta climbing well above $200, which would mark a post-split high. Back in July 2012, the company enacted a one-for-six reverse split to maintain Nasdaq listing requirements. A little over a decade and three commercialized products later, it has gained more than 1,100%. Sarepta owns a trio of injectable medicines for various forms of DMD.

One thing that should make Sarepta bulls feel comfortable is that even the most conservative price targets on the Street imply good upside. The biggest "bear," Evercore ISI, thinks the large cap biotech name is worth $139 at this juncture, which equates to 22% upside. This situation often indicates that a stock’s growth potential is inconsistent with its current price. Several technical indicators (including Bollinger Bands) suggest this volatile stock is oversold.

→ [URGENT] Altcoin Winning Picks (From Crypto Swap Profits) (Ad)

Should you invest $1,000 in Sarepta Therapeutics right now?

Before you consider Sarepta Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sarepta Therapeutics wasn't on the list.

While Sarepta Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report
Like this article? Share it with a colleague.

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Sarepta Therapeutics (SRPT)
4.7264 of 5 stars
4.73 / 5 stars
$145.61+1.3%N/A1,323.73Moderate Buy$187.72
Compare These Stocks  Add These Stocks to My Watchlist 

Featured Articles and Offers

3 Top Market Leaders Splitting Their Stocks

3 Top Market Leaders Splitting Their Stocks

Get an exclusive look at our top three stocks to watch for potential splits.

Related Videos

NVIDIA Tops Microsoft and Apple for Most Valuable Company
3 Strong Buy Stocks for a Summer Surge
Roblox Reality Check: Why the Metaverse Isn’t Saving the Stock!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines